Magnitude of the Problem
100 million surgeries per year in the US
53 million require analgesics for pain
Over half of patients report inadequate relief
In a survey of 300 patients1:
86% experienced pain after surgery
75% had moderate/extreme pain post-surgery
74% still had pain after discharge
88% received analgesic medication
80% experienced adverse effects
Need for Improvement
Suboptimal pain management leads to undesirable outcomes:
- Medical complications
- Less ambulation
- Extended length of hospital stay
Considerable emotional suffering
Significant extra costs
Despite heightened awareness and clinical advancements in pain management, there has been little improvement in post-surgical analgesia as measured by this survey of post-surgical patients.
In pre-clinical and clinical studies, the endomorphins have demonstrated potent anti-nociceptive effects, major anti-inflammatory effects, lack of respiratory depression, little to no addiction potential, less impact on constipation and cannot be converted to drugs of abuse.
In one study it was shown that the endomorphin was associated with a significant reduction in the number of days to recovery from pain after surgery. CYT-1010 is the leading endomorphin in clinical development.